- Home
- ALZN vs PRFX Comparison
ALZN vs PRFX Comparison
Compare ALZN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- PRFX
- Stock Information
- Founded
- ALZN 2016
- PRFX 2007
- Country
- ALZN United States
- PRFX Israel
- Employees
- ALZN N/A
- PRFX N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- PRFX Health Care
- Exchange
- ALZN Nasdaq
- PRFX Nasdaq
- Market Cap
- ALZN 4.5M
- PRFX 3.6M
- IPO Year
- ALZN 2021
- PRFX 2020
- Fundamental
- Price
- ALZN $3.62
- PRFX $2.06
- Analyst Decision
- ALZN Strong Buy
- PRFX Hold
- Analyst Count
- ALZN 1
- PRFX 1
- Target Price
- ALZN $180.00
- PRFX N/A
- AVG Volume (30 Days)
- ALZN 4.6M
- PRFX 55.9K
- Earning Date
- ALZN 07-29-2025
- PRFX 06-20-2025
- Dividend Yield
- ALZN N/A
- PRFX N/A
- EPS Growth
- ALZN N/A
- PRFX N/A
- EPS
- ALZN N/A
- PRFX N/A
- Revenue
- ALZN N/A
- PRFX N/A
- Revenue This Year
- ALZN $322.64
- PRFX N/A
- Revenue Next Year
- ALZN N/A
- PRFX N/A
- P/E Ratio
- ALZN N/A
- PRFX N/A
- Revenue Growth
- ALZN N/A
- PRFX N/A
- 52 Week Low
- ALZN $3.06
- PRFX $1.68
- 52 Week High
- ALZN $135.54
- PRFX $18.17
- Technical
- Relative Strength Index (RSI)
- ALZN 42.05
- PRFX 51.59
- Support Level
- ALZN $3.55
- PRFX $1.93
- Resistance Level
- ALZN $4.30
- PRFX $2.11
- Average True Range (ATR)
- ALZN 0.58
- PRFX 0.10
- MACD
- ALZN 0.11
- PRFX 0.03
- Stochastic Oscillator
- ALZN 7.44
- PRFX 80.77
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.